Ignite Creation Date:
2025-12-24 @ 7:16 PM
Ignite Modification Date:
2026-02-19 @ 2:37 PM
Study NCT ID:
NCT02181803
Status:
COMPLETED
Last Update Posted:
2020-03-27
First Post:
2014-07-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['United States']}, 'conditionBrowseModule': {'meshes': [{'id': 'D012559', 'term': 'Schizophrenia'}], 'ancestors': [{'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000729358', 'term': 'MK-8189'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrialsDisclosure@merck.com', 'phone': '1-800-672-6372', 'title': 'Senior Vice President, Global Clinical Development', 'organization': 'Merck Sharp & Dohme Corp.'}, 'certainAgreement': {'otherDetails': 'The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'There were some missing event markers in EEG recordings during data collection, these were imputed for the MMN analyses.'}}, 'adverseEventsModule': {'timeFrame': 'Up to Day 28; all-cause mortality was assessed for up to ~9 months', 'description': 'Safety was assessed by part and dose, in all participants who received as least one dose of the investigational drug. Post Study AEs were pooled across the arms in each part of the study. AEs that occurred beyond 14 days of dosing were considered Post Study AEs.', 'eventGroups': [{'id': 'EG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability', 'otherNumAtRisk': 14, 'deathsNumAtRisk': 14, 'otherNumAffected': 8, 'seriousNumAtRisk': 14, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 6, 'seriousNumAtRisk': 12, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 2, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 6, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 3, 'seriousNumAtRisk': 4, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Part 1 Panel A & B Post Study: Schizophrenic', 'description': 'Participants with Schizophrenia who received monotherapy MK-8189 or matching placebo during the treatment period, were followed for safety during the post study period', 'otherNumAtRisk': 18, 'deathsNumAtRisk': 18, 'otherNumAffected': 0, 'seriousNumAtRisk': 18, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability', 'otherNumAtRisk': 13, 'deathsNumAtRisk': 13, 'otherNumAffected': 3, 'seriousNumAtRisk': 13, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability', 'otherNumAtRisk': 17, 'deathsNumAtRisk': 17, 'otherNumAffected': 6, 'seriousNumAtRisk': 17, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability', 'otherNumAtRisk': 17, 'deathsNumAtRisk': 17, 'otherNumAffected': 7, 'seriousNumAtRisk': 17, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability', 'otherNumAtRisk': 17, 'deathsNumAtRisk': 17, 'otherNumAffected': 7, 'seriousNumAtRisk': 17, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG012', 'title': 'Part 2 Panel C Post Study: Schizophrenic', 'description': 'Participants with Schizophrenia who received add-on therapy MK-8189 or matching placebo during the treatment period, were followed for safety during the post study period', 'otherNumAtRisk': 25, 'deathsNumAtRisk': 25, 'otherNumAffected': 1, 'seriousNumAtRisk': 25, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 5, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 5, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG015', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 6, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG016', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability', 'otherNumAtRisk': 9, 'deathsNumAtRisk': 9, 'otherNumAffected': 2, 'seriousNumAtRisk': 9, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG017', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 2, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG018', 'title': 'Part 1 Panel D Post Study: Healthy', 'description': 'Healthy participants who received monotherapy MK-8189 or matching placebo during the treatment period, were followed for safety during the post study period', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 0, 'seriousNumAtRisk': 12, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Haemorrhoids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Salivary hypersecretion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Swollen tongue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Feeling hot', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Feeling of body temperature change', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Hordeolum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Concussion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Electrocardiogram QT prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Costochondritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Muscle tightness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Neck mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Torticollis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Akathisia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Cognitive disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Disturbance in attention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Dysarthria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Dystonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Head discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Muscle contractions involuntary', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Oromandibular dystonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Sleep paralysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Spasmodic dysphonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Abnormal dreams', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Anhedonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Depersonalisation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Derealisation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Psychotic disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Dermatitis contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Rash papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Flushing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Hot flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Orthostatic hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Orthostatic hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}], 'seriousEvents': [{'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 18, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 17, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189 in Schizophrenia Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability'}, {'id': 'OG010', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG011', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG012', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG015', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '67.0', 'spread': '31.7', 'groupId': 'OG000'}, {'value': '60.5', 'spread': '37.1', 'groupId': 'OG005'}, {'value': '161', 'spread': '39.8', 'groupId': 'OG006'}]}]}, {'title': 'Day 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '11', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '81.1', 'spread': '94.8', 'groupId': 'OG000'}, {'value': '80.9', 'spread': '49.1', 'groupId': 'OG005'}, {'value': '242', 'spread': '67.9', 'groupId': 'OG006'}]}]}, {'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '183', 'spread': '52.2', 'groupId': 'OG001'}, {'value': '174', 'spread': '39.4', 'groupId': 'OG006'}, {'value': '419', 'spread': '59.6', 'groupId': 'OG007'}]}]}, {'title': 'Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '148', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001'}, {'value': '387', 'spread': '42.0', 'groupId': 'OG002'}, {'value': '321', 'spread': '45.1', 'groupId': 'OG007'}, {'value': '563', 'spread': '72.3', 'groupId': 'OG008'}]}]}, {'title': 'Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '149', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001'}, {'value': '459', 'spread': '33.3', 'groupId': 'OG003'}, {'value': '517', 'spread': '52.0', 'groupId': 'OG008'}, {'value': '655', 'spread': '69.0', 'groupId': 'OG009'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1, 4, 8, 11 and 14 pre-dose and 24 hours post-dose', 'description': 'C24hr was defined as the concentration of MK-8189 observed in plasma at the 24-hour nominal sampling time after administration of MK-8189. In participants receiving MK-8189, blood samples were collected pre-dose and 24 hours post-dose to estimate C24hr following MK-8189 administration. As specified by the protocol, C24hr was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from C24 analysis.', 'unitOfMeasure': 'nM', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had C24 data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.'}, {'type': 'PRIMARY', 'title': 'Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC[0-24hr]) of MK-8189 in Schizophrenia Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability'}, {'id': 'OG010', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG011', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG012', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG015', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '1090', 'spread': '29.8', 'groupId': 'OG000'}, {'value': '1040', 'spread': '27.3', 'groupId': 'OG005'}, {'value': '2600', 'spread': '41.0', 'groupId': 'OG006'}]}]}, {'title': 'Day 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '11', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '2160', 'spread': '69.6', 'groupId': 'OG000'}, {'value': '1810', 'spread': '42.7', 'groupId': 'OG005'}, {'value': '5740', 'spread': '57.8', 'groupId': 'OG006'}]}]}, {'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '4390', 'spread': '54.4', 'groupId': 'OG001'}, {'value': '4300', 'spread': '31.5', 'groupId': 'OG006'}, {'value': '10500', 'spread': '58.7', 'groupId': 'OG007'}]}]}, {'title': 'Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '4720', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001'}, {'value': '9770', 'spread': '40.8', 'groupId': 'OG002'}, {'value': '8540', 'spread': '31.2', 'groupId': 'OG007'}, {'value': '14900', 'spread': '58.9', 'groupId': 'OG008'}]}]}, {'title': 'Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '4100', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001'}, {'value': '12300', 'spread': '27.0', 'groupId': 'OG003'}, {'value': '13200', 'spread': '38.5', 'groupId': 'OG008'}, {'value': '18700', 'spread': '59.4', 'groupId': 'OG009'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hours post-dose', 'description': 'AUC was defined as a measure of MK-8189 exposure that was calculated as the product of plasma drug concentration and time. The linear-up-log down rule was used to estimate AUC. Blood samples were collected pre-dose and up to 24 hours post-dose to estimate AUC(0-24hr) following MK-8189 administration. As specified by the protocol, AUC(0-24hr) was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from AUC(0-24hr) analysis.', 'unitOfMeasure': 'nM*hr', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had AUC(0-24hr) data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.'}, {'type': 'PRIMARY', 'title': 'Maximum Observed Post-dose Plasma Concentration (Cmax) of MK-8189 in Schizophrenia Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability'}, {'id': 'OG010', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG011', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG012', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG015', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '70.7', 'spread': '29.9', 'groupId': 'OG000'}, {'value': '63.6', 'spread': '27.5', 'groupId': 'OG005'}, {'value': '165', 'spread': '39.9', 'groupId': 'OG006'}]}]}, {'title': 'Day 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '11', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '118', 'spread': '60.7', 'groupId': 'OG000'}, {'value': '90.6', 'spread': '41.7', 'groupId': 'OG005'}, {'value': '277', 'spread': '59.7', 'groupId': 'OG006'}]}]}, {'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '212', 'spread': '52.0', 'groupId': 'OG001'}, {'value': '210', 'spread': '29.8', 'groupId': 'OG006'}, {'value': '518', 'spread': '56.5', 'groupId': 'OG007'}]}]}, {'title': 'Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '285', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001'}, {'value': '472', 'spread': '40.8', 'groupId': 'OG002'}, {'value': '409', 'spread': '28.8', 'groupId': 'OG007'}, {'value': '718', 'spread': '53.4', 'groupId': 'OG008'}]}]}, {'title': 'Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '209', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001'}, {'value': '628', 'spread': '28.5', 'groupId': 'OG003'}, {'value': '638', 'spread': '34.8', 'groupId': 'OG008'}, {'value': '1050', 'spread': '46.3', 'groupId': 'OG009'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose', 'description': 'Cmax was defined as the maximum concentration of MK-8189 observed in plasma. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Cmax following MK-8189 administration. As specified by the protocol, Cmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Cmax analysis.', 'unitOfMeasure': 'nM', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had Cmax data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.'}, {'type': 'PRIMARY', 'title': 'Time Post-dose at Which the Maximum Plasma Concentration (Tmax) of MK-8189 Was Observed in Schizophrenia Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability'}, {'id': 'OG010', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG011', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG012', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG015', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000', 'lowerLimit': '12', 'upperLimit': '23.83'}, {'value': '23.83', 'groupId': 'OG005', 'lowerLimit': '10.10', 'upperLimit': '25.27'}, {'value': '23.83', 'groupId': 'OG006', 'lowerLimit': '16', 'upperLimit': '23.83'}]}]}, {'title': 'Day 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '11', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '23.87'}, {'value': '23.83', 'groupId': 'OG005', 'lowerLimit': '6', 'upperLimit': '23.92'}, {'value': '8', 'groupId': 'OG006', 'lowerLimit': '0', 'upperLimit': '23.83'}]}]}, {'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG001', 'lowerLimit': '0', 'upperLimit': '23.98'}, {'value': '16', 'groupId': 'OG006', 'lowerLimit': '0', 'upperLimit': '23.83'}, {'value': '0', 'groupId': 'OG007', 'lowerLimit': '0', 'upperLimit': '10'}]}]}, {'title': 'Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '11', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '10', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '10.03', 'groupId': 'OG002', 'lowerLimit': '10', 'upperLimit': '23.83'}, {'value': '16', 'groupId': 'OG007', 'lowerLimit': '0', 'upperLimit': '23.83'}, {'value': '16', 'groupId': 'OG008', 'lowerLimit': '6', 'upperLimit': '23.83'}]}]}, {'title': 'Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'categories': [{'measurements': [{'value': '20', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '16', 'groupId': 'OG003', 'lowerLimit': '6', 'upperLimit': '24'}, {'value': '12', 'groupId': 'OG008', 'lowerLimit': '4', 'upperLimit': '20'}, {'value': '8', 'groupId': 'OG009', 'lowerLimit': '2', 'upperLimit': '12'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose', 'description': 'Tmax was defined as the time required post dose to reach a maximum plasma concentration of MK-8189. It was estimated as the actual sampling time at the highest MK-8189 plasma concentration. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Tmax following MK-8189 administration. As specified by the protocol, Tmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Tmax analysis.', 'unitOfMeasure': 'hr', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had Tmax data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.'}, {'type': 'PRIMARY', 'title': 'Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent t1/2) in Schizophrenia Participants on Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability'}, {'id': 'OG010', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG011', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG012', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG015', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'categories': [{'measurements': [{'value': '9.14', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'OG001'}, {'value': '8.38', 'spread': '37.8', 'groupId': 'OG003'}, {'value': '8.86', 'spread': '37.4', 'groupId': 'OG008'}, {'value': '10.4', 'spread': '43.6', 'groupId': 'OG009'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose', 'description': 't1/2 was defined as the time required to divide the MK-8189 plasma concentration by half after reaching pseudo-equilibrium. At least three quantifiable post-Cmax, terminal phase concentrations collected were used to calculate the apparent t1/2. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points on Day 14 to estimate t1/2 following MK-8189 administration. As specified by the protocol, t1/2 was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, the Day 14 timepoint was not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from t1/2 analysis.', 'unitOfMeasure': 'hr', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had t1/2 data available for Day 14. Due to differing dosing schedules, some time points were not applicable for some arms/doses (indicated by zero participants analyzed). Per protocol healthy participants (Part 3) and placebo arms were excluded.'}, {'type': 'PRIMARY', 'title': 'Number of Participants Experiencing an Adverse Event (AE)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '17', 'groupId': 'OG006'}, {'value': '17', 'groupId': 'OG007'}, {'value': '17', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '10', 'groupId': 'OG011'}, {'value': '10', 'groupId': 'OG012'}, {'value': '10', 'groupId': 'OG013'}, {'value': '9', 'groupId': 'OG014'}, {'value': '2', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability'}, {'id': 'OG010', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG011', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG012', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG015', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '7', 'groupId': 'OG007'}, {'value': '7', 'groupId': 'OG008'}, {'value': '2', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '5', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '6', 'groupId': 'OG013'}, {'value': '3', 'groupId': 'OG014'}, {'value': '2', 'groupId': 'OG015'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Day 28', 'description': 'An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced at least one AE were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who received as least one dose of the investigational drug. Per protocol, safety was assessed by part and dose.'}, {'type': 'PRIMARY', 'title': 'Number of Participants Who Discontinue From Study Treatment Due to an AE', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '17', 'groupId': 'OG006'}, {'value': '17', 'groupId': 'OG007'}, {'value': '17', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '10', 'groupId': 'OG011'}, {'value': '10', 'groupId': 'OG012'}, {'value': '10', 'groupId': 'OG013'}, {'value': '9', 'groupId': 'OG014'}, {'value': '2', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG002', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG003', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG004', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG006', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG007', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability'}, {'id': 'OG008', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG009', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability'}, {'id': 'OG010', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG011', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability'}, {'id': 'OG012', 'title': 'Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability'}, {'id': 'OG013', 'title': 'Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG014', 'title': 'Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy', 'description': 'Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability'}, {'id': 'OG015', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '1', 'groupId': 'OG013'}, {'value': '1', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Day 14', 'description': 'An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who received as least one dose of the investigational drug. Per protocol, safety was assessed by part and dose.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline at Day 13 in Mismatched Negativity (MMN) Peak Amplitude in Monotherapy MK-8189-treated Schizophrenia Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2-12 mg: Schizophrenic', 'description': 'Participants received MK-8189 escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14 or alternatively 2 mg QD Days 1-4 and 4 mg QD Days 5-14'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG002', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'OG003', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14'}, {'id': 'OG004', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy', 'description': 'Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'OG006', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy', 'description': 'Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14'}, {'id': 'OG007', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'title': 'C3', 'categories': [{'measurements': [{'value': '0.959', 'groupId': 'OG000', 'lowerLimit': '-0.218', 'upperLimit': '2.137'}]}]}, {'title': 'C4', 'categories': [{'measurements': [{'value': '0.812', 'groupId': 'OG000', 'lowerLimit': '-0.169', 'upperLimit': '1.794'}]}]}, {'title': 'Cz', 'categories': [{'measurements': [{'value': '1.170', 'groupId': 'OG000', 'lowerLimit': '-0.203', 'upperLimit': '2.543'}]}]}, {'title': 'F3', 'categories': [{'measurements': [{'value': '1.547', 'groupId': 'OG000', 'lowerLimit': '0.171', 'upperLimit': '2.922'}]}]}, {'title': 'F4', 'categories': [{'measurements': [{'value': '1.240', 'groupId': 'OG000', 'lowerLimit': '-0.006', 'upperLimit': '2.487'}]}]}, {'title': 'F7', 'categories': [{'measurements': [{'value': '0.616', 'groupId': 'OG000', 'lowerLimit': '-0.471', 'upperLimit': '1.702'}]}]}, {'title': 'F8', 'categories': [{'measurements': [{'value': '0.488', 'groupId': 'OG000', 'lowerLimit': '-1.113', 'upperLimit': '2.088'}]}]}, {'title': 'Fp1', 'categories': [{'measurements': [{'value': '0.779', 'groupId': 'OG000', 'lowerLimit': '-0.586', 'upperLimit': '2.144'}]}]}, {'title': 'Fp2', 'categories': [{'measurements': [{'value': '1.103', 'groupId': 'OG000', 'lowerLimit': '-0.480', 'upperLimit': '2.687'}]}]}, {'title': 'Fz', 'categories': [{'measurements': [{'value': '1.462', 'groupId': 'OG000', 'lowerLimit': '0.256', 'upperLimit': '2.667'}]}]}, {'title': 'O1', 'categories': [{'measurements': [{'value': '-0.099', 'groupId': 'OG000', 'lowerLimit': '-1.548', 'upperLimit': '1.350'}]}]}, {'title': 'O2', 'categories': [{'measurements': [{'value': '-0.014', 'groupId': 'OG000', 'lowerLimit': '-1.186', 'upperLimit': '1.159'}]}]}, {'title': 'P3', 'categories': [{'measurements': [{'value': '0.236', 'groupId': 'OG000', 'lowerLimit': '-1.188', 'upperLimit': '1.660'}]}]}, {'title': 'P4', 'categories': [{'measurements': [{'value': '-0.037', 'groupId': 'OG000', 'lowerLimit': '-1.233', 'upperLimit': '1.159'}]}]}, {'title': 'Pz', 'categories': [{'measurements': [{'value': '0.599', 'groupId': 'OG000', 'lowerLimit': '-0.675', 'upperLimit': '1.873'}]}]}, {'title': 'T3', 'categories': [{'measurements': [{'value': '1.018', 'groupId': 'OG000', 'lowerLimit': '-1.924', 'upperLimit': '3.960'}]}]}, {'title': 'T4', 'categories': [{'measurements': [{'value': '0.306', 'groupId': 'OG000', 'lowerLimit': '-2.667', 'upperLimit': '3.278'}]}]}, {'title': 'T5', 'categories': [{'measurements': [{'value': '-0.260', 'groupId': 'OG000', 'lowerLimit': '-3.475', 'upperLimit': '2.955'}]}]}, {'title': 'T6', 'categories': [{'measurements': [{'value': '0.178', 'groupId': 'OG000', 'lowerLimit': '-2.378', 'upperLimit': '2.734'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Day 13', 'description': 'MMN is a response to deviant tone (stimuli) measured in electroencephalogram (EEG) signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; this difference at peak waveform is MMN peak amplitude. Schizophrenic participants show reduced response to deviant stimuli. Peak amplitude change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.', 'unitOfMeasure': 'µV', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Per protocol, MMN analyses were planned and executed in all Schizophrenia participants receiving MK-8189 monotherapy (irrespective of dosing schedule) with EEG electrode data available. Per protocol MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline at Day 13 in Mismatched Negativity (MMN) Area Under Curve (AUC) in Monotherapy MK-8189-treated Schizophrenia Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2-12 mg: Schizophrenic', 'description': 'Participants received MK-8189 escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14 or alternatively 2 mg QD Days 1-4 and 4 mg QD Days 5-14'}, {'id': 'OG001', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'OG002', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'OG003', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14'}, {'id': 'OG004', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'OG005', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy', 'description': 'Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'OG006', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy', 'description': 'Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14'}, {'id': 'OG007', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'classes': [{'title': 'C3', 'categories': [{'measurements': [{'value': '-4.162', 'groupId': 'OG000', 'lowerLimit': '-25.187', 'upperLimit': '16.863'}]}]}, {'title': 'C4', 'categories': [{'measurements': [{'value': '2.800', 'groupId': 'OG000', 'lowerLimit': '-12.255', 'upperLimit': '17.856'}]}]}, {'title': 'Cz', 'categories': [{'measurements': [{'value': '2.813', 'groupId': 'OG000', 'lowerLimit': '-19.664', 'upperLimit': '25.290'}]}]}, {'title': 'F3', 'categories': [{'measurements': [{'value': '6.277', 'groupId': 'OG000', 'lowerLimit': '-12.012', 'upperLimit': '24.565'}]}]}, {'title': 'F4', 'categories': [{'measurements': [{'value': '9.814', 'groupId': 'OG000', 'lowerLimit': '-5.671', 'upperLimit': '25.299'}]}]}, {'title': 'F7', 'categories': [{'measurements': [{'value': '-0.582', 'groupId': 'OG000', 'lowerLimit': '-8.968', 'upperLimit': '7.803'}]}]}, {'title': 'F8', 'categories': [{'measurements': [{'value': '8.817', 'groupId': 'OG000', 'lowerLimit': '-3.836', 'upperLimit': '21.470'}]}]}, {'title': 'Fp1', 'categories': [{'measurements': [{'value': '8.390', 'groupId': 'OG000', 'lowerLimit': '-7.696', 'upperLimit': '24.476'}]}]}, {'title': 'Fp2', 'categories': [{'measurements': [{'value': '11.483', 'groupId': 'OG000', 'lowerLimit': '-9.046', 'upperLimit': '32.012'}]}]}, {'title': 'Fz', 'categories': [{'measurements': [{'value': '7.880', 'groupId': 'OG000', 'lowerLimit': '-14.368', 'upperLimit': '30.129'}]}]}, {'title': 'O1', 'categories': [{'measurements': [{'value': '-3.011', 'groupId': 'OG000', 'lowerLimit': '-23.898', 'upperLimit': '17.875'}]}]}, {'title': 'O2', 'categories': [{'measurements': [{'value': '-10.261', 'groupId': 'OG000', 'lowerLimit': '-24.940', 'upperLimit': '4.419'}]}]}, {'title': 'P3', 'categories': [{'measurements': [{'value': '-9.560', 'groupId': 'OG000', 'lowerLimit': '-34.188', 'upperLimit': '15.069'}]}]}, {'title': 'P4', 'categories': [{'measurements': [{'value': '-9.154', 'groupId': 'OG000', 'lowerLimit': '-29.863', 'upperLimit': '11.555'}]}]}, {'title': 'Pz', 'categories': [{'measurements': [{'value': '-10.019', 'groupId': 'OG000', 'lowerLimit': '-36.607', 'upperLimit': '16.570'}]}]}, {'title': 'T3', 'categories': [{'measurements': [{'value': '-15.594', 'groupId': 'OG000', 'lowerLimit': '-48.553', 'upperLimit': '17.365'}]}]}, {'title': 'T4', 'categories': [{'measurements': [{'value': '-3.341', 'groupId': 'OG000', 'lowerLimit': '-23.264', 'upperLimit': '16.582'}]}]}, {'title': 'T5', 'categories': [{'measurements': [{'value': '-19.394', 'groupId': 'OG000', 'lowerLimit': '-47.983', 'upperLimit': '9.194'}]}]}, {'title': 'T6', 'categories': [{'measurements': [{'value': '-12.686', 'groupId': 'OG000', 'lowerLimit': '-39.170', 'upperLimit': '13.799'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Day 13', 'description': 'MMN is a response to deviant tone (stimuli) measured in EEG signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; AUC was measured as the product of MMN amplitude and time. Schizophrenic participants show reduced response to deviant stimuli. AUC change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.', 'unitOfMeasure': 'µV*msec', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Per protocol, MMN analyses were planned and executed in all Schizophrenia participants receiving MK-8189 monotherapy (irrespective of dosing schedule) with EEG electrode data available. Per protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2-4 mg: Schizophrenic', 'description': 'Participant with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg once daily (QD) Days 1-4 and 4 mg QD Days 5-14'}, {'id': 'FG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2-12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'FG002', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'FG003', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'FG004', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14'}, {'id': 'FG005', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'FG006', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy', 'description': 'Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'FG007', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy', 'description': 'Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14'}, {'id': 'FG008', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '13'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '9'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '11'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '8'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'Forty-three schizophrenia participants and 12 healthy volunteers were randomized to either MK-8189 or placebo in Part 1 Panels A \\& B, Part 2 Panel C, or Part 3 Panel D. MK-8189 dose and schedule were modified for participants based on tolerability.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '13', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '9', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '55', 'groupId': 'BG009'}]}], 'groups': [{'id': 'BG000', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2-4 mg: Schizophrenic', 'description': 'Participant with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg once daily (QD) Days 1-4 and 4 mg QD Days 5-14'}, {'id': 'BG001', 'title': 'Part 1 Panel A & B MK-8189 Monotherapy 2-12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14.'}, {'id': 'BG002', 'title': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'BG003', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'BG004', 'title': 'Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic', 'description': 'Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14'}, {'id': 'BG005', 'title': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14'}, {'id': 'BG006', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy', 'description': 'Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14'}, {'id': 'BG007', 'title': 'Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy', 'description': 'Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14'}, {'id': 'BG008', 'title': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14'}, {'id': 'BG009', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '21.0', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'BG000'}, {'value': '44.2', 'spread': '8.7', 'groupId': 'BG001'}, {'value': '44.0', 'spread': '9.0', 'groupId': 'BG002'}, {'value': '43.8', 'spread': '8.9', 'groupId': 'BG003'}, {'value': '41.7', 'spread': '14.7', 'groupId': 'BG004'}, {'value': '44.5', 'spread': '7.6', 'groupId': 'BG005'}, {'value': '43.3', 'spread': '8.7', 'groupId': 'BG006'}, {'value': '55.0', 'spread': 'NA', 'comment': 'Measure of dispersion could not be estimated due to low number of participants analyzed', 'groupId': 'BG007'}, {'value': '43.0', 'spread': '5.7', 'groupId': 'BG008'}, {'value': '43.4', 'spread': '9.4', 'groupId': 'BG009'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '17', 'groupId': 'BG009'}]}, {'title': 'Male', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}, {'value': '7', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '38', 'groupId': 'BG009'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 55}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-08-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-03', 'completionDateStruct': {'date': '2015-04-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-03-12', 'studyFirstSubmitDate': '2014-07-02', 'resultsFirstSubmitDate': '2020-03-12', 'studyFirstSubmitQcDate': '2014-07-03', 'lastUpdatePostDateStruct': {'date': '2020-03-27', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-03-12', 'studyFirstPostDateStruct': {'date': '2014-07-04', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2020-03-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2015-04-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189 in Schizophrenia Participants', 'timeFrame': 'Day 1, 4, 8, 11 and 14 pre-dose and 24 hours post-dose', 'description': 'C24hr was defined as the concentration of MK-8189 observed in plasma at the 24-hour nominal sampling time after administration of MK-8189. In participants receiving MK-8189, blood samples were collected pre-dose and 24 hours post-dose to estimate C24hr following MK-8189 administration. As specified by the protocol, C24hr was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from C24 analysis.'}, {'measure': 'Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC[0-24hr]) of MK-8189 in Schizophrenia Participants', 'timeFrame': 'Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hours post-dose', 'description': 'AUC was defined as a measure of MK-8189 exposure that was calculated as the product of plasma drug concentration and time. The linear-up-log down rule was used to estimate AUC. Blood samples were collected pre-dose and up to 24 hours post-dose to estimate AUC(0-24hr) following MK-8189 administration. As specified by the protocol, AUC(0-24hr) was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from AUC(0-24hr) analysis.'}, {'measure': 'Maximum Observed Post-dose Plasma Concentration (Cmax) of MK-8189 in Schizophrenia Participants', 'timeFrame': 'Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose', 'description': 'Cmax was defined as the maximum concentration of MK-8189 observed in plasma. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Cmax following MK-8189 administration. As specified by the protocol, Cmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Cmax analysis.'}, {'measure': 'Time Post-dose at Which the Maximum Plasma Concentration (Tmax) of MK-8189 Was Observed in Schizophrenia Participants', 'timeFrame': 'Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose', 'description': 'Tmax was defined as the time required post dose to reach a maximum plasma concentration of MK-8189. It was estimated as the actual sampling time at the highest MK-8189 plasma concentration. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Tmax following MK-8189 administration. As specified by the protocol, Tmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Tmax analysis.'}, {'measure': 'Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent t1/2) in Schizophrenia Participants on Day 14', 'timeFrame': 'Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose', 'description': 't1/2 was defined as the time required to divide the MK-8189 plasma concentration by half after reaching pseudo-equilibrium. At least three quantifiable post-Cmax, terminal phase concentrations collected were used to calculate the apparent t1/2. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points on Day 14 to estimate t1/2 following MK-8189 administration. As specified by the protocol, t1/2 was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, the Day 14 timepoint was not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from t1/2 analysis.'}, {'measure': 'Number of Participants Experiencing an Adverse Event (AE)', 'timeFrame': 'Up to Day 28', 'description': 'An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced at least one AE were reported.'}, {'measure': 'Number of Participants Who Discontinue From Study Treatment Due to an AE', 'timeFrame': 'Up to Day 14', 'description': 'An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE were reported.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline at Day 13 in Mismatched Negativity (MMN) Peak Amplitude in Monotherapy MK-8189-treated Schizophrenia Participants', 'timeFrame': 'Baseline and Day 13', 'description': 'MMN is a response to deviant tone (stimuli) measured in electroencephalogram (EEG) signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; this difference at peak waveform is MMN peak amplitude. Schizophrenic participants show reduced response to deviant stimuli. Peak amplitude change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.'}, {'measure': 'Change From Baseline at Day 13 in Mismatched Negativity (MMN) Area Under Curve (AUC) in Monotherapy MK-8189-treated Schizophrenia Participants', 'timeFrame': 'Baseline and Day 13', 'description': 'MMN is a response to deviant tone (stimuli) measured in EEG signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; AUC was measured as the product of MMN amplitude and time. Schizophrenic participants show reduced response to deviant stimuli. AUC change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Schizophrenia']}, 'descriptionModule': {'briefSummary': 'This 3-part dose titration study will assess MK-8189 safety, tolerability, pharmacokinetics (PK), and central nervous system activity. Part 1 (Panels A and B) will assess MK-8189 administered as monotherapy in participants with schizophrenia. Part 2 (Panel C) will assess MK-8189 administered as add-on to atypical antipsychotic treatment in participants with schizophrenia. Part 3 (Panel D) will assess monotherapy with MK-8189 in healthy participants, including those of Japanese descent. The primary hypothesis is that there is at least one dose of MK-8189 that is generally safe and well-tolerated which will have the desired PK parameters in participants with schizophrenia.', 'detailedDescription': 'As specified by Phase 1 protocol-flexible language in the protocol, modifications to the dose or dosing regimen can be made to achieve the scientific goals of the trial objectives and/or ensure appropriate safety of the trial participants. The proposed doses for each Part may be adjusted downward based on evaluation of safety, tolerability, and pharmacokinetic data observed in previous panels.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\nINCLUSION CRITERIA FOR SCHIZOPHRENIA PARTICIPANTS\n\n* Male or non-pregnant and non-breast feeding female. If participant is male with a female partner of child-bearing potential, participant must agree to use a medically acceptable method of contraception during the trial and for 120 days after the last dose of trial drug. If their partner is pregnant, males must agree to use a condom\n* Body Mass Index (BMI) ≥ 18.5 and ≤ 40 kg/m\\^2\n* Meet diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria with the onset of the first episode being no less than 2 years prior to study entry\n* Be in the non-acute phase of illness and clinically stable for 3 months prior to screening\n* History of receiving and tolerating antipsychotic medication within the usual dose range employed for schizophrenia\n* Participants with hypothyroidism, diabetes, high blood pressure, chronic respiratory conditions or other mild forms of these medical conditions could be considered as candidates for study enrollment if their condition is stable and the prescribed dose and regimen of medication is stable for at least 3 months prior to screening and there are no expected changes in comedication during the study\n* Has a negative urinary drug screen at screening\n\nINCLUSION CRITERIA FOR HEALTHY PARTICIPANTS\n\n* Male, or non-pregnant and non-breast feeding female of Japanese or non-Japanese descent. If participant is male with a female partner of child-bearing potential, participant must agree to use a medically acceptable method of contraception during the trial and for 120 days after the last dose of trial drug. If their partner is pregnant, males must agree to use a condom\n* Body Mass Index (BMI) ≥ 18.5 and ≤ 35 kg/m\\^2\n* In good health\n* Nonsmoker and/or has not used nicotine or nicotine-containing products (e.g., nicotine patch) for at least approximately 3 months\n* Has a negative urinary drug screen at screening\n\nExclusion Criteria:\n\nEXCLUSION CRITERIA FOR SCHIZOPHRENIA PARTICIPANTS\n\n* DSM-IV axis I psychiatric diagnosis other than schizophrenia or schizoaffective disorder within one month of screening\n* Has evidence or history of mental retardation, borderline personality disorder, anxiety disorder, or organic brain syndrome\n* History of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia\n* Untreated or uncompensated clinically significant renal, endocrine, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cardiovascular, hematological, immunological or cerebrovascular disease, malignance, allergic disease or other chronic and/or degenerative process at screening\n* Has a history of cancer (malignancy) with certain exceptions\n* Treatment with clozapine for schizophrenia or treatment with monoamine oxidase inhibitors within 3 months of screening\n* Received a parenteral depot antipsychotic medication within 3 months of screening\n* Participated in another investigational study within 4 weeks, prior to screening\n\nEXCLUSION CRITERIA FOR HEALTHY PARTICIPANTS\n\n* History of clinically significant endocrine, gastrointestinal, cardiovascular (including hypertension, angina, coronary artery disease, valvular disease, heart rate or rhythm abnormalities), hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic seizures) abnormalities or diseases\n* Mentally or legally incapacitated\n* History of clinically diagnosed depression, anxiety disorder, or any history of psychiatric disorders having required drug treatment or hospitalization\n* History of cancer (malignancy)\n* Unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies throughout the trial\n* Participated in another investigational study within 4 weeks, prior to screening'}, 'identificationModule': {'nctId': 'NCT02181803', 'briefTitle': 'MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merck Sharp & Dohme LLC'}, 'officialTitle': 'A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients', 'orgStudyIdInfo': {'id': '8189-003'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic', 'description': 'Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability', 'interventionNames': ['Drug: MK-8189']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic', 'description': 'Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability', 'interventionNames': ['Drug: MK-8189', 'Drug: Base Monotherapy']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic', 'description': 'Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability', 'interventionNames': ['Drug: MK-8189', 'Drug: Base Monotherapy']}, {'type': 'EXPERIMENTAL', 'label': 'Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy', 'description': 'Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability', 'interventionNames': ['Drug: MK-8189']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'description': 'Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy', 'interventionNames': ['Drug: Placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'description': 'Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy', 'interventionNames': ['Drug: Placebo', 'Drug: Base Monotherapy']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part 3 Panel D Placebo Monotherapy: Healthy', 'description': 'Healthy participants will receive dose-matched placebo to MK-8189 monotherapy', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'MK-8189', 'type': 'DRUG', 'description': 'MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg', 'armGroupLabels': ['Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic', 'Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic', 'Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic', 'Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD', 'armGroupLabels': ['Part 1 Panel A & B Placebo Monotherapy: Schizophrenic', 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic', 'Part 3 Panel D Placebo Monotherapy: Healthy']}, {'name': 'Base Monotherapy', 'type': 'DRUG', 'description': 'For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \\[not to exceed daily dose of 6 mg\\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.', 'armGroupLabels': ['Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic', 'Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic', 'Part 2 Panel C Placebo Add-on Therapy: Schizophrenic']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merck Sharp & Dohme LLC'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}